1 Min Read
LONDON, June 24 (Reuters) - GlaxoSmithKline Plc : * Albiglutide combination therapy demonstrated statistically significant
reduction in hba1c from baseline compared to placebo * Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.